Abstract
Tocainide is an antiarrhythmic agent belonging to class IB that was primarily used for suppression of symptomatic ventricular arrhythmias. Tocainide was also reported to relieve pain such as tic douloureux, trigemina neuralgia in humans and tinnitus. Significant antinociception, as assayed on the hot-plate test, was observed after intraperitoneal injection of tocainide, too. By the mid-1980s tocainide was emerging as a more consistently effective treatment for myotonic disorders. Numerous reports of serious adverse reactions led to the use of tocainide being discontinued, even though research on tocainide and its analogues, endowed with a better pharmacological profile, is still in progress for their potential usefulness in the treatment of myotonias. This review is focused on the description of the different synthetic routes to racemic and optically active tocainide developed in the last decades, as well as analytical studies regarding enantioseparation methods. Finally, some analogues of tocainide reported in the literature, most of which with pharmacological studies, have been mentioned.
Keywords: Antiarrhythmic agents, antimyotonic agents, sodium channel blockers, tocainide, hNav1.4, myotonias.
Current Medicinal Chemistry
Title:A Focus on the Synthesis and Pharmacokinetics of Tocainide and its Analogues
Volume: 25 Issue: 42
Author(s): Alessia Carocci, Filomena Corbo, Giovanni Lentini, Maria Maddalena Cavalluzzi, Carlo Franchini and Alessia Catalano*
Affiliation:
- Department of Pharmacy-Drug Sciences, University of Bari “Aldo Moro”, via Orabona 4, 70126 Bari,Italy
Keywords: Antiarrhythmic agents, antimyotonic agents, sodium channel blockers, tocainide, hNav1.4, myotonias.
Abstract: Tocainide is an antiarrhythmic agent belonging to class IB that was primarily used for suppression of symptomatic ventricular arrhythmias. Tocainide was also reported to relieve pain such as tic douloureux, trigemina neuralgia in humans and tinnitus. Significant antinociception, as assayed on the hot-plate test, was observed after intraperitoneal injection of tocainide, too. By the mid-1980s tocainide was emerging as a more consistently effective treatment for myotonic disorders. Numerous reports of serious adverse reactions led to the use of tocainide being discontinued, even though research on tocainide and its analogues, endowed with a better pharmacological profile, is still in progress for their potential usefulness in the treatment of myotonias. This review is focused on the description of the different synthetic routes to racemic and optically active tocainide developed in the last decades, as well as analytical studies regarding enantioseparation methods. Finally, some analogues of tocainide reported in the literature, most of which with pharmacological studies, have been mentioned.
Export Options
About this article
Cite this article as:
Carocci Alessia , Corbo Filomena , Lentini Giovanni , Cavalluzzi Maddalena Maria , Franchini Carlo and Catalano Alessia*, A Focus on the Synthesis and Pharmacokinetics of Tocainide and its Analogues, Current Medicinal Chemistry 2018; 25 (42) . https://dx.doi.org/10.2174/0929867325666180327104320
DOI https://dx.doi.org/10.2174/0929867325666180327104320 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
7-prenyloxi-6-methoxycoumarin from Polygala sabulosa A.W. Bennett Regulates p38 MAPK and NF-kB Pathways Inhibiting the Inflammation Induced by Carrageenan in the Mouse Model of Pleurisy
Inflammation & Allergy - Drug Targets (Discontinued) n-3 Polyunsaturated Fatty Acids as Signal Transduction Modulators and Therapeutical Agents in Cancer
Current Signal Transduction Therapy Multifunctional Hydroxyapatite-based Nanoparticles for Biomedicine: Recent Progress in Drug Delivery and Local Controlled Release
Current Mechanics and Advanced Materials Spirulina paltensis: Food and Function
Current Nutrition & Food Science Insights into the Platelet Releasate
Current Pharmaceutical Design Dexmedetomidine Use in General Anaesthesia
Current Drug Targets Novel Drugs Targeting Microtubules: the Role of Epothilones
Current Pharmaceutical Design Natural Products with Antiangiogenic and Antivasculogenic Mimicry Activity
Mini-Reviews in Medicinal Chemistry Conjugation Approaches for Construction of Aptamer-Modified Nanoparticles for Application in Imaging
Current Topics in Medicinal Chemistry Targeting Inflammatory Bowel Diseases by Nanocarriers Loaded with Small and Biopharmaceutical Anti-Inflammatory Drugs
Current Pharmaceutical Design Bioactive Chromone Derivatives – Structural Diversity
Current Bioactive Compounds Drosophila Neoplasias: Clues Towards the Understanding of Human Cancers
Current Genomics Stimulation of Tumor-Specific Immunity by p5 HER-2/neu Generated Peptide Encapsulated in Nano-liposomes with High Phase Transition Temperature Phospholipids
Current Drug Delivery Targeting Opioid and Neurokinin-1 Receptors to Treat Alcoholism
Current Medicinal Chemistry Role of Lipoxins and Resolvins as Anti-Inflammatory and Proresolving Mediators in Colon Cancer
Current Molecular Medicine Application of Diet-derived Taste Active Components for Clinical Nutrition: Perspectives from Ancient AyurvedicMedical Science, Space Medicine, and Modern Clinical Nutrition
Current Pharmaceutical Design Development of Prolactin Receptor Antagonists: Same Goal, Different Ways
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Development of Novel Combined Time and pH-Dependent based Drug Delivery Systems for Targeting 5-Fluorouracil to the Colon
Current Drug Delivery Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Malignant Glioma In Vitro Models: On the Utilization of Stem-like Cells
Current Cancer Drug Targets